

Cover Story
Conversation with The Cancer Letter
By Claire Marie Porter and Paul Goldberg
Over the course of his first six months as NCI director, Anthony Letai has contended with federal budget turbulence, a record-setting government shutdown, and concerns about the flow of over research dollars.
Cancer Policy
In Brief


Clinical Roundup
Drugs & Targets
Trending Stories
- FDA’s second rejection of Replimune’s melanoma treatment stirs worry among oncologists, patients
“Patients are owed another review.” - Mayo Clinic AI detects pancreatic cancer up to three years before diagnosis, validation study finds
- By adding specialists to USPSTF, Kennedy would reshape the functioning and decisions of the influential health panel
Ransohoff: “The task force’s job is to describe the evidence fairly, and that’s done best with objective, detached methodologists” - ASCO & The Conquer Cancer Foundation announce merit awards
- CDC’s recommendation to delay infant hepatitis B shot is likely to raise infections, JAMA studies show
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members














